After Hours Summary: FGEN -30% falls harply after clarification on roxadustat, but AKBA +10.2% up on the news; MAXN -7% falls on earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SGH +0.6%
Companies trading higher in after hours in reaction to news: AKBA +10.2% (FGEN's news is seen as a positive for AKBA's competing anemia drug candidate), NVST +9% (to join S&P MidCap 400), IDCC +5.7% (to join S&P SmallCap 600), QGEN +4% (launches QIAseq DIRECT SARS-CoV-2 Kit), XTNT +3.9% (stock offering), NCLH +2.8% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), RCL +2.4% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), CCL +1.8% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), KXIN +1.6% (RENN announces $6 mln equity investment in KXIN), NUVA +0.5% (Simplify Disc receives approval from FDA for two-level cervical total disc replacement), AMZN +0.1% (Bezos says co is supportive of a rise in the corporate tax rate), ZEN +0.1% (names new Chief Marketing Officer), LLY +0.1% (LLY and INCY announce extension of review period for baricitinib sNDA), CXW +0.1% (files for mixed securities shelf offering)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: MAXN -7% (also announces major new initiative to expand in US solar market)
Companies trading lower in after hours in reaction to news: FGEN -30% (provides clarification of certain prior disclosures on roxadustat), FIXX -10.2% (stock offering), PHR -6.7% (stock offering), IONS -5.8% (announces private placement of $500 mln of convertible notes), LI -5% (convertible notes offering), OM -4.5% (stock offering), UPST -3.7% (stock offering), GNW -2.9% (decides to terminate merger agreement with China Oceanwide), RENN -1.6% (RENN announces $6 mln equity investment in KXIN), EVRI -1.4% (chairman retires), FOA -0.5% (new CFO), INCY -0.5% (LLY and INCY announce extension of review period for baricitinib sNDA), PCG -0.3% (issues statement disputing criminal charges related to 2019 Kincade Fire)